Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504268 · ClinicalTrials.gov registry record · Phase 3
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 994
- Enrollment target
NCT02504268 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 994 participants.
The verdict
NCT02504268, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 994 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
Interventions
- DRUG Abatacept
- DRUG Methotrexate
- OTHER Abatacept Placebo
- OTHER Methotrexate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 994 participants |
| Start Date | 2015-09-03 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504268
The ClinicalTrials.gov registry entry for NCT02504268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 994 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT02504268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02504268 about?
NCT02504268 is a clinical study titled "Effects of Abatacept in Patients With Early Rheumatoid Arthritis". The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
What is the current status of trial NCT02504268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 994 participants. The study started on 2015-09-03. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT02504268?
The interventions under investigation include: Abatacept (DRUG), Methotrexate (DRUG), Abatacept Placebo (OTHER), Methotrexate Placebo (OTHER).
Who is sponsoring clinical trial NCT02504268?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.